MA52501A - Inhibiteurs de kras g12c et leurs procédés d'utilisation - Google Patents
Inhibiteurs de kras g12c et leurs procédés d'utilisationInfo
- Publication number
- MA52501A MA52501A MA052501A MA52501A MA52501A MA 52501 A MA52501 A MA 52501A MA 052501 A MA052501 A MA 052501A MA 52501 A MA52501 A MA 52501A MA 52501 A MA52501 A MA 52501A
- Authority
- MA
- Morocco
- Prior art keywords
- kras
- inhibitors
- procedures
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862667282P | 2018-05-04 | 2018-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52501A true MA52501A (fr) | 2021-03-10 |
Family
ID=66912909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052501A MA52501A (fr) | 2018-05-04 | 2019-05-03 | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11090304B2 (fr) |
| EP (1) | EP3788038B1 (fr) |
| JP (1) | JP7266043B2 (fr) |
| AU (1) | AU2019262589B2 (fr) |
| CA (1) | CA3098574A1 (fr) |
| MA (1) | MA52501A (fr) |
| MX (1) | MX2020010836A (fr) |
| WO (1) | WO2019213516A1 (fr) |
Families Citing this family (157)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| CA2981530A1 (fr) | 2015-04-10 | 2016-10-13 | Araxes Pharma Llc | Composes quinazoline substitues et leurs procedes d'utilisation |
| US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058792A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines kras portant la mutation g12c |
| WO2017087528A1 (fr) | 2015-11-16 | 2017-05-26 | Araxes Pharma Llc | Composés quinazoline substitués en position 2 comprenant un groupe hétérocyclique substitué et leur méthode d'utilisation |
| US10532042B2 (en) | 2016-12-22 | 2020-01-14 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| EP3573954A1 (fr) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Composés benzohétéroaromatiques bicycliques fusionnés et leurs procédés d'utilisation |
| EP3573964A1 (fr) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Composés à base de benzothiophène et de benzothiazole et leurs procédés d'utilisation |
| US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
| JP7327802B2 (ja) | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法 |
| WO2018140514A1 (fr) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Dérivés de 1-(6-(3-hydroxynaphtalen-1-yl)quinazolin-2-yl)azétidin-1-yl)prop-2-en-1-one et composés similaires utilisés en tant qu'inhibiteurs de kras g12c pour le traitement du cancer |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| EP3630747A1 (fr) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Dérivés de quinazoline utilisés en tant que modulateurs de kras, hras ou nras mutants |
| WO2018218071A1 (fr) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Composés et leurs procédés d'utilisation pour le traitement du cancer |
| EP3630745A2 (fr) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Inhibiteurs covalents de kras |
| EP4403175A3 (fr) | 2017-09-08 | 2024-10-02 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| JP7361722B2 (ja) | 2018-05-04 | 2023-10-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤及び同一物の使用方法 |
| MA52501A (fr) * | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| WO2019217691A1 (fr) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Inhibiteurs de kras g12c pour le traitement du cancer |
| CA3098885A1 (fr) | 2018-06-01 | 2019-12-05 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procedes d'utilisation |
| US11285156B2 (en) | 2018-06-12 | 2022-03-29 | Amgen Inc. | Substituted piperazines as KRAS G12C inhibitors |
| US12134620B2 (en) | 2018-08-01 | 2024-11-05 | Araxes Pharma Llc | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer |
| CN112119075B (zh) | 2018-08-16 | 2024-03-12 | 豪夫迈·罗氏有限公司 | 稠环化合物 |
| JP7451419B2 (ja) | 2018-10-26 | 2024-03-18 | 大鵬薬品工業株式会社 | 新規なインダゾール化合物又はその塩 |
| JP7516029B2 (ja) * | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| EP3883565A1 (fr) | 2018-11-19 | 2021-09-29 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| CA3120383A1 (fr) * | 2018-11-29 | 2020-06-04 | Araxes Pharma Llc | Composes et procedes d'utilisation associes pour le traitement du cancer |
| CN113166078B (zh) * | 2018-12-10 | 2024-11-19 | 伊迪亚生物科学有限公司 | 2-氧代喹唑啉衍生物作为甲硫氨酸腺苷转移酶2a抑制剂 |
| US20220152026A1 (en) | 2019-02-12 | 2022-05-19 | Novartis Ag | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
| EP3738593A1 (fr) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosage d'inhibiteur de kras pour le traitement de cancers |
| CA3140394A1 (fr) | 2019-05-21 | 2020-11-26 | Amgen Inc. | Formes a l'etat solide |
| MX2021014096A (es) * | 2019-05-21 | 2022-02-11 | Inventisbio Co Ltd | Compuestos heterociclicos, metodos de preparacion y usos de estos. |
| CR20210665A (es) | 2019-05-21 | 2022-01-25 | Amgen Inc | Formas en estado sólido |
| CN113423703B (zh) * | 2019-05-29 | 2024-08-02 | 上海翰森生物医药科技有限公司 | 含氮杂环类衍生物调节剂、其制备方法和应用 |
| WO2020239123A1 (fr) * | 2019-05-31 | 2020-12-03 | 上海翰森生物医药科技有限公司 | Modulateur de dérivé hétérocyclique aromatique et son procédé de préparation et son utilisation |
| CN112047937B (zh) * | 2019-06-06 | 2023-04-07 | 劲方医药科技(上海)有限公司 | 四氢吡啶并[3,4-d]嘧啶-2(1H)-酮类化合物，其制法与医药上的用途 |
| CN114008037B (zh) * | 2019-06-24 | 2024-06-21 | 广东新契生物医药科技有限公司 | 作为kras g12c抑制剂的杂环化合物 |
| CN110256421A (zh) * | 2019-06-26 | 2019-09-20 | 微境生物医药科技(上海)有限公司 | Kras-g12c抑制剂 |
| AR119821A1 (es) * | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| CN114728968B (zh) * | 2019-09-20 | 2024-11-15 | 上海济煜医药科技有限公司 | 稠合吡啶酮类化合物及其制备方法和应用 |
| US11697657B2 (en) | 2019-10-28 | 2023-07-11 | Merck Sharp & Dohme Llc | Small molecule inhibitors of KRAS G12C mutant |
| LT4053118T (lt) * | 2019-10-30 | 2024-12-10 | Genfleet Therapeutics (Shanghai) Inc. | Pakeistas heterociklinis junginys su sujungtais žiedais, jo paruošimo būdas ir naudojimas farmacijoje |
| EP4054719A1 (fr) | 2019-11-04 | 2022-09-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2021091967A1 (fr) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| CN113286794B (zh) * | 2019-11-04 | 2024-03-12 | 北京加科思新药研发有限公司 | Kras突变蛋白抑制剂 |
| AU2020377925A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| CN112851663B (zh) * | 2019-11-12 | 2023-07-18 | 博瑞生物医药（苏州）股份有限公司 | 一种并杂环化合物及其用途 |
| EP4058432A1 (fr) * | 2019-11-14 | 2022-09-21 | Amgen Inc. | Synthèse améliorée de composés inhibiteurs de kras g12c |
| CN120463705A (zh) | 2019-11-14 | 2025-08-12 | 美国安进公司 | Kras g12c抑制剂化合物的改善的合成 |
| JP2023505100A (ja) | 2019-11-27 | 2023-02-08 | レボリューション メディシンズ インコーポレイテッド | 共有ｒａｓ阻害剤及びその使用 |
| US12479834B2 (en) | 2019-11-29 | 2025-11-25 | Taiho Pharmaceutical Co., Ltd. | Phenol compound or salt thereof |
| WO2021104431A1 (fr) * | 2019-11-29 | 2021-06-03 | 苏州信诺维医药科技股份有限公司 | Composé inhibiteur de kras g12c et son utilisation |
| WO2021120045A1 (fr) | 2019-12-18 | 2021-06-24 | InventisBio Co., Ltd. | Composés hétérocycliques, leurs procédés de préparation et utilisations associées |
| US20230089255A1 (en) * | 2019-12-19 | 2023-03-23 | Bristol-Myers Squibb Company | Combinations of dgk inhibitors and checkpoint antagonists |
| WO2021120890A1 (fr) * | 2019-12-20 | 2021-06-24 | Novartis Ag | Dérivés pyrazolyle utiles en tant qu'agents anticancéreux |
| AU2020412698A1 (en) | 2019-12-23 | 2022-08-18 | Bristol-Myers Squibb Company | Substituted piperazine derivatives useful as T cell activators |
| WO2021139678A1 (fr) * | 2020-01-07 | 2021-07-15 | 广州百霆医药科技有限公司 | Inhibiteur pyridopyrimidine de protéine mutante kras g12c |
| WO2021143693A1 (fr) * | 2020-01-13 | 2021-07-22 | 苏州泽璟生物制药股份有限公司 | Dérivé de pyridone ou de pyrimidine aryle ou hétéroaryle, son procédé de préparation et son utilisation |
| CN114671866A (zh) * | 2020-12-25 | 2022-06-28 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| CN113105448A (zh) * | 2020-01-13 | 2021-07-13 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| CN113801113A (zh) * | 2020-06-12 | 2021-12-17 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| US11530218B2 (en) | 2020-01-20 | 2022-12-20 | Incyte Corporation | Spiro compounds as inhibitors of KRAS |
| CN115003668A (zh) * | 2020-01-21 | 2022-09-02 | 南京明德新药研发有限公司 | 作为kras抑制剂的大环类化合物 |
| CN112159405B (zh) * | 2020-02-04 | 2021-09-14 | 广州必贝特医药技术有限公司 | 吡啶并嘧啶酮类化合物及其应用 |
| CN113248521B (zh) * | 2020-02-11 | 2023-07-18 | 上海和誉生物医药科技有限公司 | 一种k-ras g12c抑制剂及其制备方法和应用 |
| US20230099858A1 (en) * | 2020-02-20 | 2023-03-30 | Beta Pharma, Inc. | Pyridopyrimidine derivatives as kras inhibitors |
| WO2023205701A1 (fr) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Hétérocycles macrocycliques et leurs utilisations |
| US20230143751A1 (en) * | 2020-02-24 | 2023-05-11 | Shanghai Zheye Biotechnology Co. Ltd. | Aromatic Compound And Use Thereof In Preparing Antineoplastic Drugs |
| WO2021175199A1 (fr) * | 2020-03-02 | 2021-09-10 | 上海喆邺生物科技有限公司 | Composé hétérocyclique aromatique et son application dans un médicament |
| TW202144345A (zh) * | 2020-03-17 | 2021-12-01 | 大陸商北京加科思新藥研發有限公司 | Ｋｒａｓ突變蛋白抑制劑 |
| US20230357272A1 (en) * | 2020-04-03 | 2023-11-09 | Medshine Discovery Inc. | Octahydropyrazinodiazanaphthyridine dione compounds |
| TW202208355A (zh) | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
| JP7741100B2 (ja) | 2020-05-04 | 2025-09-17 | アムジェン インコーポレイテッド | ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法 |
| US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
| WO2021244555A1 (fr) * | 2020-06-02 | 2021-12-09 | 上海喆邺生物科技有限公司 | Intermédiaire chiral et son procédé de préparation |
| US20230023009A1 (en) * | 2020-06-05 | 2023-01-26 | Sparcbio Llc | Heterocyclic compounds and methods of use thereof |
| WO2021248095A1 (fr) * | 2020-06-05 | 2021-12-09 | Sparcbio Llc | Composés hétérocycliques et leurs procédés d'utilisation |
| WO2021248082A1 (fr) * | 2020-06-05 | 2021-12-09 | Sparcbio Llc | Composés hétérocycliques et leurs procédés d'utilisation |
| WO2021252339A1 (fr) * | 2020-06-08 | 2021-12-16 | Accutar Biotechnology, Inc. | Composés de purine -2,6-dione substitués en tant qu'inhibiteurs de kras |
| EP4165040B1 (fr) * | 2020-06-10 | 2025-08-27 | Ideaya Biosciences, Inc. | Dérivés de 2-aminoquinazolinone comme inhibiteurs de la méthionine adénosyltransférase 2a |
| WO2021249563A1 (fr) * | 2020-06-12 | 2021-12-16 | 苏州泽璟生物制药股份有限公司 | Dérivé de pyridone ou de pyrimidone aryle ou hétéroaryle, son procédé de préparation et son utilisation |
| EP4168002A1 (fr) | 2020-06-18 | 2023-04-26 | Revolution Medicines, Inc. | Méthodes de retardement, de prévention et de traitement de la résistance acquise aux inhibiteurs de ras |
| EP4194452A4 (fr) * | 2020-08-02 | 2024-08-21 | Shanghai Zheye Biotechnology Co., Ltd. | Composé aromatique et son application dans un médicament antitumoral |
| CN114075195A (zh) * | 2020-08-21 | 2022-02-22 | 广东东阳光药业有限公司 | 嘧啶酮衍生物及其在药物中的应用 |
| US11999752B2 (en) | 2020-08-28 | 2024-06-04 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of KRAS |
| CA3187757A1 (fr) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Utilisation d'inhibiteurs de sos1 pour traiter des malignites a mutations de shp2 |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| KR20230094198A (ko) | 2020-09-23 | 2023-06-27 | 에라스카, 아이엔씨. | 3환식 피리돈 및 피리미돈 |
| WO2022072783A1 (fr) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Composés diones bicycliques en tant qu'inhibiteurs de kras |
| WO2022081912A2 (fr) * | 2020-10-15 | 2022-04-21 | Kumquat Biosciences Inc. | Hétérocycles et leurs utilisations |
| MX2023005078A (es) * | 2020-10-30 | 2023-05-16 | Novartis Ag | Nuevas formas cristalinas de un compuesto inhibidor de kras g12c. |
| US20240025896A1 (en) | 2020-11-20 | 2024-01-25 | Amgen Inc. | Process for preparing 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione |
| WO2022111521A1 (fr) * | 2020-11-24 | 2022-06-02 | 杭州多域生物技术有限公司 | Composé aromatique, son procédé de préparation et son utilisation |
| CN116390915A (zh) * | 2020-11-24 | 2023-07-04 | 杭州多域生物技术有限公司 | 一种芳香化合物、其制备方法及应用 |
| CN115803328B (zh) * | 2020-11-24 | 2024-07-23 | 成都百裕制药股份有限公司 | 哌嗪-2,3-二酮衍生物及其在医药上的应用 |
| EP4253376B1 (fr) * | 2020-11-26 | 2025-07-30 | Shanghai Hansoh Biomedical Co., Ltd. | Forme saline et forme cristalline d'un dérivé hétérocyclique contenant de l'azote, leur procédé de préparation et leur utilisation |
| WO2022121839A1 (fr) * | 2020-12-08 | 2022-06-16 | 上海和誉生物医药科技有限公司 | Dérivé de pyrido[2,3-d]pyrimidin-2(1h)-one, son procédé de préparation et son application |
| CN116529249A (zh) * | 2020-12-18 | 2023-08-01 | 正大天晴药业集团股份有限公司 | 吡啶并嘧啶酮类化合物 |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| IL303917A (en) * | 2020-12-22 | 2023-08-01 | Novartis Ag | Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor for the treatment of cancers |
| WO2022133731A1 (fr) * | 2020-12-22 | 2022-06-30 | Novartis Ag | Combinaisons pharmaceutiques comprenant un inhibiteur de kras g12c et utilisations d'un inhibiteur de kras g12c et pour le traitement de cancers |
| CN116940346A (zh) * | 2021-03-11 | 2023-10-24 | 益方生物科技(上海)股份有限公司 | 固体分散体 |
| WO2022204112A1 (fr) | 2021-03-22 | 2022-09-29 | Incyte Corporation | Inhibiteurs d'imidazole et triazole kras |
| WO2022222911A1 (fr) * | 2021-04-19 | 2022-10-27 | 武汉人福创新药物研发中心有限公司 | Composé pyrimidone et son utilisation |
| AR125782A1 (es) | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | Inhibidores de ras |
| CN118852330A (zh) | 2021-05-05 | 2024-10-29 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
| US20240417408A1 (en) * | 2021-05-28 | 2024-12-19 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
| WO2022266069A1 (fr) * | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Inhibiteurs tricycliques de kras g12d |
| WO2022266206A1 (fr) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Conjugués d'inhibiteurs de kras |
| WO2022265974A1 (fr) * | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Inhibiteurs de kras tricycliques substitués par un aminohétérocycle |
| US20240383921A1 (en) * | 2021-06-16 | 2024-11-21 | Erasca, Inc. | Amide and urea-containing tricyclic kras inhibitors |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| EP4363412A4 (fr) * | 2021-06-30 | 2025-05-14 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs à petites molécules de mutant de kras g12d |
| PE20241127A1 (es) | 2021-07-07 | 2024-05-24 | Incyte Corp | Compuestos triciclicos como inhibidores de kras |
| CN117157292A (zh) * | 2021-07-16 | 2023-12-01 | 苏州赞荣医药科技有限公司 | Kras g12d抑制剂和其用途 |
| EP4396187A1 (fr) | 2021-08-31 | 2024-07-10 | Incyte Corporation | Composés de naphtyridine en tant qu'inhibiteurs de kras |
| MX2024002561A (es) | 2021-09-01 | 2024-03-20 | Novartis Ag | Combinaciones farmaceuticas que comprenden un inhibidor de tead y usos de las mismas para el tratamiento de canceres. |
| EP4389751A1 (fr) | 2021-09-03 | 2024-06-26 | Kumquat Biosciences Inc. | Composés hétérocycliques et leurs utilisations |
| WO2023041059A1 (fr) * | 2021-09-18 | 2023-03-23 | 南京明德新药研发有限公司 | Composé d'octahydropyrazinodiazanaphtyridine dione et sa forme cristalline |
| WO2023049697A1 (fr) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Composés hétéro-tricycliques utilisés en tant qu'inhibiteurs de kras |
| EP4408536A1 (fr) | 2021-10-01 | 2024-08-07 | Incyte Corporation | Inhibiteurs de kras tels que la pyrazoloquinoline |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023064857A1 (fr) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Composés de quinoléine utiles en tant qu'inhibiteurs de kras |
| CN118139861A (zh) * | 2021-11-05 | 2024-06-04 | 苏州信诺维医药科技股份有限公司 | Kras突变体抑制剂的晶型、其制备方法及其应用 |
| WO2023114954A1 (fr) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Composés pyrazolopyrazine utilisés comme inhibiteurs de la shp2 |
| EP4227307A1 (fr) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Composés pyrazolopyrazine en tant qu'inhibiteurs de shp2 |
| KR20240156373A (ko) | 2022-03-07 | 2024-10-29 | 암젠 인크 | 4-메틸-2-프로판-2-일-피리딘-3-카르보니트릴의 제조 방법 |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| WO2023173014A1 (fr) * | 2022-03-09 | 2023-09-14 | Blossomhill Therapeutics, Inc. | Inhibiteurs de kras et leur utilisation |
| CN116327956B (zh) * | 2022-04-01 | 2025-11-28 | 劲方医药科技(上海)股份有限公司 | 药物组合物、其用途及癌症的治疗方法 |
| US20250295664A1 (en) | 2022-04-04 | 2025-09-25 | Sanofi | Therapeutic combination of kras g12c inhibitor and tead inhibitor |
| WO2023199180A1 (fr) | 2022-04-11 | 2023-10-19 | Novartis Ag | Utilisations thérapeutiques d'un inhibiteur de krasg12c |
| WO2023212549A1 (fr) * | 2022-04-26 | 2023-11-02 | Erasca, Inc. | Pyridones et pyrimidones tricycliques |
| US20250313577A1 (en) * | 2022-04-26 | 2025-10-09 | Erasca, Inc | Tricyclic pyridones and pyrimidones |
| IL317476A (en) | 2022-06-10 | 2025-02-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2024102421A2 (fr) | 2022-11-09 | 2024-05-16 | Revolution Medicines, Inc. | Composés, complexes, et leurs procédés de préparation et d'utilisation |
| TW202504611A (zh) | 2023-03-30 | 2025-02-01 | 美商銳新醫藥公司 | 用於誘導ｒａｓ ｇｔｐ水解之組合物及其用途 |
| WO2024211712A1 (fr) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Composés macrocycliques condensés en tant qu'inhibiteurs de ras |
| WO2024211663A1 (fr) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Composés macrocycliques condensés en tant qu'inhibiteurs de ras |
| WO2024216048A1 (fr) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Formes cristallines d'inhibiteurs de ras, compositions les contenant et leurs procédés d'utilisation |
| US20240352036A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| AU2024276994A1 (en) | 2023-05-24 | 2025-10-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| TW202502779A (zh) | 2023-06-30 | 2025-01-16 | 美商金橘生物科技公司 | 取代的雜芳族胺及其用途 |
| WO2025034702A1 (fr) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 destiné à être utilisé dans le traitement d'une maladie ou d'un trouble lié à une protéine ras |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| US12466840B2 (en) | 2023-10-20 | 2025-11-11 | Merck Sharp & Dohme Llc | Small molecule inhibitors of KRAS proteins |
| WO2025171055A1 (fr) | 2024-02-06 | 2025-08-14 | Kumquat Biosciences Inc. | Conjugués hétérocycliques et leurs utilisations |
| WO2025171296A1 (fr) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2025230971A1 (fr) | 2024-04-30 | 2025-11-06 | Kumquat Biosciences Inc. | Hétérocycles macrocycliques en tant qu'agents anticancéreux |
| WO2025240847A1 (fr) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| CN118994048A (zh) * | 2024-08-01 | 2024-11-22 | 东南大学 | 一种基于苯并恶唑的环境敏感性荧光染料及其制备方法 |
Family Cites Families (236)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4232027A (en) | 1979-01-29 | 1980-11-04 | E. R. Squibb & Sons, Inc. | 1,2-Dihydro-2-oxo-4-phenyl-3-quinolinecarbonitrile derivatives |
| GB2116183B (en) | 1982-03-03 | 1985-06-05 | Genentech Inc | Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| JP2762522B2 (ja) | 1989-03-06 | 1998-06-04 | 藤沢薬品工業株式会社 | 血管新生阻害剤 |
| GB8912336D0 (en) | 1989-05-30 | 1989-07-12 | Smithkline Beckman Intercredit | Compounds |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
| US5892112A (en) | 1990-11-21 | 1999-04-06 | Glycomed Incorporated | Process for preparing synthetic matrix metalloprotease inhibitors |
| US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
| US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
| CA2066898A1 (fr) | 1991-04-29 | 1992-10-30 | Chuan Shih | Composes pharmaceutiques |
| SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
| GB9125660D0 (en) | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Novel compound |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| DE4221054A1 (de) | 1992-06-30 | 1994-01-05 | Herbst Bremer Goldschlaegerei | Präparat zur prophylaktischen und therapeutischen Behandlung von Karies sowie Verfahren zum Herstellen desselben |
| ZA935111B (en) | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| EP0669929B1 (fr) | 1992-11-13 | 2007-01-03 | Immunex Corporation | Ligand d'elk, une cytokine |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5516658A (en) | 1993-08-20 | 1996-05-14 | Immunex Corporation | DNA encoding cytokines that bind the cell surface receptor hek |
| AU693475B2 (en) | 1993-10-01 | 1998-07-02 | Novartis Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
| US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| CA2175215C (fr) | 1993-11-19 | 2008-06-03 | Yat Sun Or | Analogues semi-synthetiques de rapamycine (macrolides) utilises comme immunomodulateurs |
| US5912253A (en) | 1993-12-17 | 1999-06-15 | Novartis Ag | Rapamycin derivatives |
| US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| AU2096895A (en) | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| EP1464706A3 (fr) | 1994-04-15 | 2004-11-03 | Amgen Inc., | HEK5, HEK7, HEK8 et HEK11: des récepteurs protéine tyrosine kinase d'analogues de l'EPH |
| ATE159257T1 (de) | 1994-05-03 | 1997-11-15 | Ciba Geigy Ag | Pyrrolopyrimidinderivate mit antiproliferativer wirkung |
| US6303769B1 (en) | 1994-07-08 | 2001-10-16 | Immunex Corporation | Lerk-5 dna |
| US5919905A (en) | 1994-10-05 | 1999-07-06 | Immunex Corporation | Cytokine designated LERK-6 |
| US6057124A (en) | 1995-01-27 | 2000-05-02 | Amgen Inc. | Nucleic acids encoding ligands for HEK4 receptors |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| EP3103799B1 (fr) | 1995-03-30 | 2018-06-06 | OSI Pharmaceuticals, LLC | Derives de quinazoline |
| PT819129E (pt) | 1995-04-03 | 2001-01-31 | Novartis Ag | Derivados pirazole e processos para a sua preparacao |
| PT821671E (pt) | 1995-04-20 | 2001-04-30 | Pfizer | Derivados do acido arilsulfonil hidroxamico como inibidores de mmp e tnf |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| ES2187660T3 (es) | 1995-06-09 | 2003-06-16 | Novartis Ag | Derivados de rapamicina. |
| PL188959B1 (pl) | 1995-07-06 | 2005-05-31 | Novartis Ag | Pirolopirymidyny i sposoby ich wytwarzania |
| DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| DK0780386T3 (da) | 1995-12-20 | 2003-02-03 | Hoffmann La Roche | Matrixmetalloproteaseinhibitorer |
| ES2177925T3 (es) | 1996-01-23 | 2002-12-16 | Novartis Ag | Pirrolopirimidinas y procedimientos para su preparacion. |
| JP3406763B2 (ja) | 1996-01-30 | 2003-05-12 | 東レ・ダウコーニング・シリコーン株式会社 | シリコーンゴム組成物 |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
| DE19608588A1 (de) | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE19629652A1 (de) | 1996-03-06 | 1998-01-29 | Thomae Gmbh Dr K | 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE59710417D1 (de) | 1996-03-15 | 2003-08-14 | Novartis Ag | N-7 HETEROCYCLYL-PYRROLO[ 2,3-d]PYRIMIDINE UND IHRE VERWENDUNG |
| PL190489B1 (pl) | 1996-04-12 | 2005-12-30 | Warner Lambert Co | Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie |
| GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
| BR9709959A (pt) | 1996-06-24 | 2000-05-09 | Pfizer | Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas |
| EP0818442A3 (fr) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Dérivés cycliques de sulfones comme inhibiteurs de métalloprotéinase et de la production du facteur de nécrose des tumeurs |
| AU735648B2 (en) | 1996-07-12 | 2001-07-12 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| ATE227283T1 (de) | 1996-07-13 | 2002-11-15 | Glaxo Group Ltd | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
| TR199900048T2 (xx) | 1996-07-13 | 1999-04-21 | Glaxo Group Limited | Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| SI0923585T1 (en) | 1996-07-18 | 2002-08-31 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| AU4055697A (en) | 1996-08-16 | 1998-03-06 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| CA2262421C (fr) | 1996-08-23 | 2007-10-02 | Novartis Ag | Pyrrolopyrimidines substituees et procede pour leur preparation |
| PL331895A1 (en) | 1996-08-23 | 1999-08-16 | Pfizer | Arylosulphonylamino derivatives of hydroxamic acid |
| AU4779897A (en) | 1996-10-02 | 1998-04-24 | Novartis Ag | Fused pyrazole derivatives and processes for their preparation |
| EP0929553B1 (fr) | 1996-10-02 | 2005-03-16 | Novartis AG | Derives de pyrimidine et procedes de preparation de ces derniers |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| EP0837063A1 (fr) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | Dérivés de 4-aminoquinazoline |
| GB9621757D0 (en) | 1996-10-18 | 1996-12-11 | Ciba Geigy Ag | Phenyl-substituted bicyclic heterocyclyl derivatives and their use |
| PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
| HUP0000852A2 (hu) | 1997-02-03 | 2001-05-28 | Pfizer Products Inc. | Aril-szulfonil-amino-hidroxámsav-származékok, valamint e vegyületeket tartalmazó gyógyászati készítmények |
| EP0964864B1 (fr) | 1997-02-05 | 2008-04-09 | Warner-Lambert Company LLC | Pyrido 2,3d pyrimidines et 4-aminopyrimidines en tant qu'inhibiteurs de la proliferation cellulaire |
| EP0966438A1 (fr) | 1997-02-07 | 1999-12-29 | Pfizer Inc. | Derives du n-hxdroxy-beta-sulfonyl-propionamide et leur utilisation comme inhibiteurs des metalloproteases matrices |
| JP3710489B2 (ja) | 1997-02-11 | 2005-10-26 | ファイザー・インク | アリールスルホニルヒドロキサム酸誘導体 |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| US6150395A (en) | 1997-05-30 | 2000-11-21 | The Regents Of The University Of California | Indole-3-carbinol (I3C) derivatives and methods |
| AU8689298A (en) | 1997-08-05 | 1999-03-01 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
| US6214872B1 (en) | 1997-08-08 | 2001-04-10 | Pfizer Inc. | Aryloxyarylsulfonylamino hydroxamic acid derivatives |
| EP1025228A4 (fr) | 1997-10-21 | 2002-09-18 | Human Genome Sciences Inc | Proteines tr11, tr11sv1 et tr11sv2 de type recepteur du facteur de necrose tumorale humain |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| WO1999040196A1 (fr) | 1998-02-09 | 1999-08-12 | Genentech, Inc. | Nouveaux homologues recepteurs du facteur necrosant des tumeurs et acides nucleiques codant ceux-ci |
| AU756838B2 (en) | 1998-03-04 | 2003-01-23 | Bristol-Myers Squibb Company | Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| AU759226B2 (en) | 1998-05-29 | 2003-04-10 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| CA2336848A1 (fr) | 1998-07-10 | 2000-01-20 | Merck & Co., Inc. | Nouveaux inhibiteurs de l'angiogenese |
| CA2341409A1 (fr) | 1998-08-31 | 2000-03-09 | Merck And Co., Inc. | Nouveaux inhibiteurs d'angiogenese |
| EP1004578B1 (fr) | 1998-11-05 | 2004-02-25 | Pfizer Products Inc. | Dérivés d'hydroxamide de l'acide 5-oxo-pyrrolidine-2-carboxylique |
| ES2384160T3 (es) | 1999-01-13 | 2012-07-02 | Bayer Healthcare Llc | Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38 |
| JP4673977B2 (ja) | 1999-03-30 | 2011-04-20 | ノバルティス アーゲー | 炎症性疾患治療用フタラジン誘導体 |
| GB9912961D0 (en) | 1999-06-03 | 1999-08-04 | Pfizer Ltd | Metalloprotease inhibitors |
| US6521424B2 (en) | 1999-06-07 | 2003-02-18 | Immunex Corporation | Recombinant expression of Tek antagonists |
| DE60027564T3 (de) | 1999-06-07 | 2009-07-23 | Immunex Corp., Thousand Oaks | Tek-antagonisten |
| DE60036945T2 (de) | 1999-07-12 | 2008-08-21 | Genentech, Inc., South San Francisco | Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen |
| ATE264863T1 (de) | 1999-08-24 | 2004-05-15 | Ariad Gene Therapeutics Inc | 28-epirapaloge |
| HK1049664B (en) | 1999-11-05 | 2006-11-10 | Genzyme Corporation | Quinazoline derivatives as vegf inhibitors |
| EP1233943B1 (fr) | 1999-11-24 | 2011-06-29 | Sugen, Inc. | Formulations pour agents pharmaceutiques ionisables comme acides libres ou bases libres |
| US6515004B1 (en) | 1999-12-15 | 2003-02-04 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| US6727225B2 (en) | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
| AU4721901A (en) | 2000-02-25 | 2001-09-03 | Immunex Corp | Integrin antagonists |
| CN1219753C (zh) | 2000-07-19 | 2005-09-21 | 沃尼尔·朗伯公司 | 4－碘苯氨基苯氧肟酸的氧合酯 |
| US6630500B2 (en) | 2000-08-25 | 2003-10-07 | Cephalon, Inc. | Selected fused pyrrolocarbazoles |
| KR100847169B1 (ko) | 2000-12-21 | 2008-07-17 | 글락소 그룹 리미티드 | 혈관형성 조절제로서의 피리미딘아민 |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US20020147198A1 (en) | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
| US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| WO2004063195A1 (fr) | 2003-01-03 | 2004-07-29 | Sloan-Kettering Institute For Cancer Research | Inhibiteurs de kinases a base de pyridopyrimidine |
| KR20060052681A (ko) | 2003-05-23 | 2006-05-19 | 와이어쓰 | Ｇｉｔｒ 리간드, ｇｉｔｒ 리간드-연관 분자, 항체 및그의 용도 |
| PL1646634T3 (pl) | 2003-07-08 | 2009-04-30 | Novartis Ag | Zastosowanie rapamycyny i pochodnych rapamycyny w leczeniu utraty kości |
| WO2005007190A1 (fr) | 2003-07-11 | 2005-01-27 | Schering Corporation | Agonistes ou antagonistes du recepteur du facteur de necrose tumorale induit par les glucocorticoides (gitr) ou de son ligand utilises dans le traitement des troubles immuns, des infections et du cancer |
| EP1648900A4 (fr) | 2003-07-11 | 2010-02-10 | Ariad Pharma Inc | Macrocycles contenant du phosphore |
| AR045134A1 (es) | 2003-07-29 | 2005-10-19 | Smithkline Beecham Plc | Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic |
| EP1656376A1 (fr) | 2003-08-22 | 2006-05-17 | Avanir Pharmaceuticals | Derives de naphtyridine substitues servant d'inhibiteurs de facteur d'inhibition de la migration des macrophages et leur utilisation pour traiter des maladies humaines |
| EP1692318A4 (fr) | 2003-12-02 | 2008-04-02 | Genzyme Corp | Compositions et methodes pour le diagnostic et le traitement du cancer du poumon |
| GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| WO2006083289A2 (fr) | 2004-06-04 | 2006-08-10 | Duke University | Methodes et compositions ameliorant l'immunite par depletion in vivo de l'activite cellulaire immunosuppressive |
| MX2007002312A (es) | 2004-08-26 | 2007-04-16 | Pfizer | Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa. |
| GT200500287A (es) | 2004-10-13 | 2006-04-17 | Analogos de 17-hidroxiwortmanina como inhibidores de pi3k | |
| KR20070073791A (ko) | 2004-10-18 | 2007-07-10 | 암젠 인코포레이티드 | 티아디아졸 화합물 및 이의 사용방법 |
| US7812135B2 (en) | 2005-03-25 | 2010-10-12 | Tolerrx, Inc. | GITR-binding antibodies |
| NZ563193A (en) | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| AU2006293620A1 (en) | 2005-09-20 | 2007-03-29 | Pfizer Products Inc. | Dosage forms and methods of treatment using a tyrosine kinase inhibitor |
| MY149143A (en) | 2006-01-18 | 2013-07-15 | Amgen Inc | Thiazole compounds as protien kinase b (pkb) inhibitors |
| US20110212086A1 (en) | 2006-01-19 | 2011-09-01 | Genzyme Corporation | GITR Antibodies For The Treatment of Cancer |
| AR064155A1 (es) | 2006-12-07 | 2009-03-18 | Piramed Ltd | Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso |
| MX2009009913A (es) | 2007-03-23 | 2009-10-16 | Amgen Inc | Derivados de quinolina o benzopirazina y sus usos para el tratamiento de enfermedades inflamatorias, enfermedades autoinmunitarias o varias clases de canceres. |
| US8193199B2 (en) | 2007-03-23 | 2012-06-05 | Amgen Inc. | Heterocyclic compounds and their uses |
| CA2680853C (fr) | 2007-03-23 | 2012-07-17 | Amgen Inc. | Derives de quinoleine ou quinoxaline 3-substituee et leur utilisation en tant qu'inhibiteurs de phosphatidylinositol 3-kinase (pi3k) |
| US8557830B2 (en) | 2007-06-07 | 2013-10-15 | Amgen Inc. | RAF kinase modulators and methods of use |
| AU2008275589B2 (en) | 2007-07-12 | 2013-11-21 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| CA2693473A1 (fr) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazoles modulateurs de l'activite de pkb |
| EP2173728A2 (fr) | 2007-07-17 | 2010-04-14 | Amgen Inc. | Modulateurs hétérocycliques de pkb |
| CA2694136C (fr) | 2007-08-02 | 2013-09-17 | Amgen Inc. | Modulateur de la pi3 kinase et leurs procedes d'utilisation |
| WO2009036082A2 (fr) | 2007-09-12 | 2009-03-19 | Genentech, Inc. | Combinaisons de composés inhibiteurs des phosphoinositide 3-kinases et agents chimiothérapeutiques, et leurs procédés d'utilisation |
| WO2009055730A1 (fr) | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Procédé de préparation de composés de thiénopyrimidine |
| NZ586069A (en) | 2007-12-19 | 2012-05-25 | Amgen Inc | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| WO2009085230A1 (fr) | 2007-12-19 | 2009-07-09 | Amgen Inc. | Inhibiteurs de la pi3 kinase |
| EP2278973B1 (fr) | 2008-04-07 | 2011-11-02 | Amgen Inc. | Amino-pyridines/pyrimidines spirocycliques et gem-disubstituées en tant qu'inhibiteurs du cycle cellulaire |
| MX315904B (es) | 2008-05-30 | 2013-11-29 | Amgen Inc | Inhibidores de fosfoinosituro-3 cinasa. |
| AU2009266873A1 (en) | 2008-07-02 | 2010-01-07 | Emergent Product Development Seattle, Llc | TGF-beta antagonist multi-target binding proteins |
| WO2010030002A1 (fr) | 2008-09-12 | 2010-03-18 | 国立大学法人三重大学 | Cellule capable d'exprimer un ligand gitr exogène |
| EP2387570A1 (fr) | 2009-01-15 | 2011-11-23 | Amgen, Inc | Thiazoles substitués par fluoroisoquinoléine et leurs méthodes d'application |
| CA2752527C (fr) | 2009-02-18 | 2014-09-23 | Amgen Inc. | Composes d'indole ou benzimidazole convenant comme inhibiteurs de la kinase mtor |
| US8729074B2 (en) | 2009-03-20 | 2014-05-20 | Amgen Inc. | Inhibitors of PI3 kinase |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| JP2012526836A (ja) | 2009-05-13 | 2012-11-01 | アムジエン・インコーポレーテツド | Ｐｉｋｋ阻害薬としてのヘテロアリール化合物 |
| JP2012531436A (ja) | 2009-06-25 | 2012-12-10 | アムジエン・インコーポレーテツド | 複素環式化合物およびそれらのｐｉ３ｋ活性阻害剤としての使用 |
| CA2765817A1 (fr) | 2009-06-25 | 2010-12-29 | Amgen Inc. | Derives 4h-pyrido[1,2-a]pyrimidin-4-one en tant qu'inhibiteurs de pi3k |
| US20100331306A1 (en) | 2009-06-25 | 2010-12-30 | Amgen Inc. | Heterocyclic compounds and their uses |
| AU2010265932B2 (en) | 2009-06-25 | 2014-11-20 | Amgen Inc. | Heterocyclic compounds and their uses |
| EP3023438B1 (fr) | 2009-09-03 | 2020-03-11 | Merck Sharp & Dohme Corp. | Anticorps anti-gitr |
| PL2475368T3 (pl) | 2009-09-11 | 2015-05-29 | Amgen Inc | N-(4-((3-(2-amino-4-pirymidynylo)-2-pirydynylo)oksy)fenylo)-4-(4-metylo-2-tienylo)-1-ftalazynoamina do stosowania w leczeniu raka opornego na czynniki antymitotyczne |
| GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
| RS55229B1 (sr) | 2009-12-29 | 2017-02-28 | Emergent Product Dev Seattle | Heterodimerni vezujući proteini i njihove upotrebe |
| WO2012142498A2 (fr) | 2011-04-13 | 2012-10-18 | Innovimmune Biotherapeutics, Inc. | Facteurs d'inhibition de la migration des macrophages (mif) et leurs utilisations |
| WO2013039954A1 (fr) | 2011-09-14 | 2013-03-21 | Sanofi | Anticorps anti-gitr |
| EP2836482B1 (fr) | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions et méthodes pour le traitement du cancer |
| CA2881279C (fr) | 2012-08-07 | 2020-07-07 | Merck Patent Gmbh | Derives de pyridopyrimidine en tant qu'inhibiteurs de proteine kinase |
| CA2904393A1 (fr) | 2013-03-15 | 2014-09-25 | Araxes Pharma Llc | Inhibiteurs covalents de k-ras g12c |
| UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| WO2014143659A1 (fr) | 2013-03-15 | 2014-09-18 | Araxes Pharma Llc | Inhibiteurs covalents irréversibles de la gtpase k-ras g12c |
| GB201312059D0 (en) | 2013-07-05 | 2013-08-21 | Univ Leuven Kath | Novel GAK modulators |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| KR20160076519A (ko) | 2013-10-10 | 2016-06-30 | 아락세스 파마 엘엘씨 | Kras g12c 억제제 |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CN106458996B (zh) | 2014-01-20 | 2020-11-03 | 克里弗生物科学公司 | 作为p97复合物的抑制剂的稠合嘧啶 |
| WO2016035008A1 (fr) | 2014-09-04 | 2016-03-10 | Lupin Limited | Dérivés de pyridopyrimidine utilisés comme inhibiteurs de mek |
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| WO2016049565A1 (fr) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions et procédés pour inhiber la ras |
| AR102094A1 (es) | 2014-09-25 | 2017-02-01 | Araxes Pharma Llc | Inhibidores de proteínas kras con una mutación g12c |
| CA2981530A1 (fr) | 2015-04-10 | 2016-10-13 | Araxes Pharma Llc | Composes quinazoline substitues et leurs procedes d'utilisation |
| CA2982360A1 (fr) | 2015-04-15 | 2016-10-20 | Liansheng Li | Inhibiteurs tricycliques condenses de kras et procedes pour les utiliser |
| EP3325447A1 (fr) | 2015-07-22 | 2018-05-30 | Araxes Pharma LLC | Composés de quinazoline substitués et leur utilisation en tant qu'inhibiteurs de protéines kras, hras et/ou nras mutantes g12c |
| US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058792A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines kras portant la mutation g12c |
| WO2017058902A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines mutantes kras g12c |
| US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058768A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines kras portant la mutation g12c |
| WO2017058805A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines kras portant la mutation g12c |
| WO2017087528A1 (fr) | 2015-11-16 | 2017-05-26 | Araxes Pharma Llc | Composés quinazoline substitués en position 2 comprenant un groupe hétérocyclique substitué et leur méthode d'utilisation |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| KR20180091097A (ko) | 2015-12-23 | 2018-08-14 | 그리노파티온 바이오테크 게엠베하 | 보체 활성화를 억제하기 위한 폴리펩티드 |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| CA3024523A1 (fr) * | 2016-05-18 | 2017-11-23 | Mirati Therapeutics, Inc. | Inhibiteurs de kras g12c |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| JP2019529484A (ja) | 2016-09-29 | 2019-10-17 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤 |
| WO2018068017A1 (fr) | 2016-10-07 | 2018-04-12 | Araxes Pharma Llc | Composés hétérocycliques en tant qu'inhibiteurs de ras et leurs procédés d'utilisation |
| CA3042929A1 (fr) * | 2016-11-08 | 2018-05-17 | Cancer Research Technology Limited | Derives de pyrimidinone en tant qu'inhibiteurs de cdc7 |
| US10532042B2 (en) | 2016-12-22 | 2020-01-14 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| EP3573966A1 (fr) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Composés n-hétérocycliques fusionnés et leurs procédés d'utilisation |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| EP3630747A1 (fr) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Dérivés de quinazoline utilisés en tant que modulateurs de kras, hras ou nras mutants |
| EP4403175A3 (fr) * | 2017-09-08 | 2024-10-02 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| BR112020009818A2 (pt) * | 2017-11-15 | 2020-11-03 | Mirati Therapeutics, Inc. | inibidores kras g12c |
| JP7361722B2 (ja) | 2018-05-04 | 2023-10-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤及び同一物の使用方法 |
| MA52501A (fr) * | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| WO2019217691A1 (fr) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Inhibiteurs de kras g12c pour le traitement du cancer |
| CA3098885A1 (fr) | 2018-06-01 | 2019-12-05 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procedes d'utilisation |
| EP3802537A1 (fr) | 2018-06-11 | 2021-04-14 | Amgen Inc. | Inhibiteurs de kras g12c pour le traitement du cancer |
| US11285156B2 (en) | 2018-06-12 | 2022-03-29 | Amgen Inc. | Substituted piperazines as KRAS G12C inhibitors |
| CN112313231B (zh) | 2018-06-21 | 2023-05-09 | 詹森药业有限公司 | Oga抑制剂化合物 |
| AU2019291101A1 (en) | 2018-06-21 | 2021-01-07 | Janssen Pharmaceutica Nv | OGA inhibitor compounds |
| US11528607B2 (en) | 2018-08-13 | 2022-12-13 | Apple Inc. | Techniques in evolved packet core for restricted local operator services access |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| EP3883565A1 (fr) | 2018-11-19 | 2021-09-29 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| CA3128062A1 (fr) | 2019-01-29 | 2020-08-06 | Brightgene Bio-Medical Technology Co., Ltd. | Compose de benzopyridone heterocyclique et son utilisation |
| EP3738593A1 (fr) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosage d'inhibiteur de kras pour le traitement de cancers |
| CR20210665A (es) | 2019-05-21 | 2022-01-25 | Amgen Inc | Formas en estado sólido |
| CA3140394A1 (fr) | 2019-05-21 | 2020-11-26 | Amgen Inc. | Formes a l'etat solide |
| WO2021081212A1 (fr) | 2019-10-24 | 2021-04-29 | Amgen Inc. | Dérivés de pyridopyrimidine utiles en tant qu'inhibiteurs de kras g12c et de kras g12d dans le traitement du cancer |
| WO2021126816A1 (fr) | 2019-12-16 | 2021-06-24 | Amgen Inc. | Schéma posologique d'un inhibiteur du kras g12c |
| EP4650006A2 (fr) | 2021-01-08 | 2025-11-19 | Amgen Inc. | Utilisation d'un inhibiteur de kras g12c dans le traitement de cancers |
-
2019
- 2019-05-03 MA MA052501A patent/MA52501A/fr unknown
- 2019-05-03 EP EP19731372.9A patent/EP3788038B1/fr active Active
- 2019-05-03 WO PCT/US2019/030593 patent/WO2019213516A1/fr not_active Ceased
- 2019-05-03 AU AU2019262589A patent/AU2019262589B2/en active Active
- 2019-05-03 US US16/402,538 patent/US11090304B2/en active Active
- 2019-05-03 CA CA3098574A patent/CA3098574A1/fr active Pending
- 2019-05-03 JP JP2020555848A patent/JP7266043B2/ja active Active
- 2019-05-03 MX MX2020010836A patent/MX2020010836A/es unknown
-
2021
- 2021-06-30 US US17/363,878 patent/US11766436B2/en active Active
-
2023
- 2023-06-23 US US18/213,464 patent/US12440491B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3788038A1 (fr) | 2021-03-10 |
| AU2019262589A1 (en) | 2020-10-29 |
| JP2021521194A (ja) | 2021-08-26 |
| US20240050430A1 (en) | 2024-02-15 |
| US11090304B2 (en) | 2021-08-17 |
| US11766436B2 (en) | 2023-09-26 |
| EP3788038B1 (fr) | 2023-10-11 |
| US12440491B2 (en) | 2025-10-14 |
| MX2020010836A (es) | 2021-01-08 |
| CA3098574A1 (fr) | 2019-11-07 |
| AU2019262589B2 (en) | 2022-07-07 |
| US20190343838A1 (en) | 2019-11-14 |
| WO2019213516A1 (fr) | 2019-11-07 |
| US20220395504A1 (en) | 2022-12-15 |
| JP7266043B2 (ja) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51848A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52765A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52501A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52496A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA50077A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA48772A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA55136A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA54261A (fr) | Inhibiteurs de pcsk9 et leurs procédés d'utilisation | |
| EP3710430A4 (fr) | Inhibiteurs d'acss2 et leurs procédés d'utilisation | |
| MA54327A (fr) | Inhibiteurs de kras g12c | |
| MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
| MA54538A (fr) | Inhibiteurs d'apol1 et leurs procédés d'utilisation | |
| EP3911640A4 (fr) | Inhibiteurs de pcsk9 et leurs procédés d'utilisation | |
| MA52963A (fr) | Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation | |
| EP3684364A4 (fr) | Pyridazinones et leurs procédés d'utilisation | |
| EP3846808A4 (fr) | Inhibiteurs de papd5 et leurs procédés d'utilisation | |
| EP3962481A4 (fr) | Inhibiteurs de kcnt1 et procédés d'utilisation | |
| MA53015A (fr) | Anticorps anti-sirp-bêta1 et procédés d'utilisation associés | |
| MA51837A (fr) | Inhibiteurs de l'arginase et leurs procédés d'utilisation | |
| EP3852533A4 (fr) | Pyridazinones et leurs procédés d'utilisation | |
| EP3765006A4 (fr) | Inhibiteurs d'arginase et procédés d'utilisation | |
| EP3941475A4 (fr) | Pyridazinones et leurs procédés d'utilisation | |
| EP3810615A4 (fr) | Inhibiteurs d'arginase et procédés d'utilisation | |
| EP4031144A4 (fr) | Benzimidazoles et leurs procédés d'utilisation | |
| EP3806834A4 (fr) | Clamps dynamiques et leurs procédés d'utilisation |